Video

It's an Exciting Time for Myelodysplastic Syndrome

Author(s):

Amy DeZern, M.D.

Learning more about MDS will lead to better diagnostics and more personalized treatments.

It’s an exciting time in the field of myelodysplastic syndrome (MDS), explained Amy DeZern, M.D., associate professor of Oncology and Medicine at the Johns Hopkins University School of Medicine.

Researchers and practitioners alike are learning more about the biology of the disease, as well as the molecular mutations that come along with it. This is helping to differentiate different subtypes of MDS — it is not a heterogenous disease – which will lead to better diagnostic and prognostic accuracy, as well as paving the way for the use of targeted therapy in this space.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content
Jane Biehl is a 12-year survivor of a very rare form of blood cancer, known as myelodysplastic syndrome (MDS). Catch up on all of Jane’s blogs here!
July 18th 2025

Max The Butterfly: Hope and Resurrection After Cancer

Jane Biehl Ph.D.
Butterflies are believed to be a symbol of resurrection and hope. This is an inspiring story about this phenomenon.
Image of Jane B.
July 7th 2025

What You Can’t Do With Cancer: Talking About the Negatives

Jane Biehl Ph.D.
I’ve survived rare blood cancer for 15 years, but the lasting side effects have taken a toll — even so, I still find purpose, joy and reasons to keep going.
Image of Jane.
June 6th 2025

The Invisibility of Blood Cancers to Others

Jane Biehl Ph.D.
I describe what it is like to have an “invisible” cancer.
Jane Biehl is a 12-year survivor of a very rare form of blood cancer, known as myelodysplastic syndrome (MDS). Catch up on all of Jane’s blogs here!
June 2nd 2025

Cancer Survivors Look Forward, Not Backward

Jane Biehl Ph.D.
As a cancer survivor I explain the importance of looking forward to life.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
Jane Biehl is a 12-year survivor of a very rare form of blood cancer, known as myelodysplastic syndrome (MDS). Catch up on all of Jane’s blogs here!
April 24th 2025

Taking Charge of My Care and Advocacy Following a Cancer Diagnosis

Jane Biehl Ph.D.
After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.